ANDA Impurity Product Specifications Updated In FDA Draft Guidance
Executive Summary
A revised FDA draft guidance updates recommendations on the listing and qualification of degradation products in ANDAs
You may also be interested in...
Generic drug impurities draft guidance
FDA releases draft guidance entitled "ANDAs: Impurities in Drug Substances." The document, published in the Federal Register Jan. 31, is the first revision of the original 1999 guidance. The draft guidance suggests companies use stability studies, chemical development studies and routine batch analysis to test for impurities, which can be qualified in four ways...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials